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ABSTRACT
P53-binding protein 1 (53BP1) mediates DNA repair
pathway choice and promotes checkpoint activation.
Chromatin marks induced by DNA double-strand
breaks and recognized by 53BP1 enable focal accu-
mulation of this multifunctional repair factor at dam-
aged chromatin. Here, we unveil an additional level of
regulation of 53BP1 outside repair foci. 53BP1 move-
ments are constrained throughout the nucleoplasm
and increase in response to DNA damage. 53BP1
interacts with the structural protein NuMA, which
controls 53BP1 diffusion. This interaction, and colo-
calization between the two proteins in vitro and in
breast tissues, is reduced after DNA damage. In cell
lines and breast carcinoma NuMA prevents 53BP1
accumulation at DNA breaks, and high NuMA ex-
pression predicts better patient outcomes. Manipu-
lating NuMA expression alters PARP inhibitor sen-
sitivity of BRCA1-null cells, end-joining activity, and
immunoglobulin class switching that rely on 53BP1.
We propose a mechanism involving the sequestra-
tion of 53BP1 by NuMA in the absence of DNA dam-
age. Such a mechanism may have evolved to disable
repair functions and may be a decisive factor for tu-
mor responses to genotoxic treatments.
INTRODUCTION
DNA double-strand breaks (DSB) trigger a rapid and com-
prehensive DNA damage response (DDR) that leads to
checkpoint signaling and cell cycle arrest, repair factor re-
cruitment to the damage sites, and DNA repair. The pre-
cise orchestration of this response is critical for cell and
organism survival (1). Most DDR factors are permanent
residents of the nucleoplasm that are not synthesized de
novo during the DDR. Rather, repair foci formation relies
on posttranslational modifications of histones and DDR
factors. DSB are processed predominantly by two com-
peting pathways: Error-prone nonhomologous end-joining
(NHEJ) and homologous recombination (HR). HR re-
stores the genetic information from the sister chromatids
and the committing step for this pathway is DNA end re-
section.
53BP1 is a multifunctional DDR protein that plays
an important role in repair pathway choice: 53BP1 and
its effector RIF1 compete with BRCA1 to prevent CtIP-
mediated resection and, as a consequence, antagonize HR
in favor of NHEJ (2–5). Additionally, RIF1 recruits the
shielding complex that suppresses resection (6–9). This ef-
fect is fine-tuned by SCAI, which progressively associates
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with 53BP1, thereby displacingRIF1 and enabling BRCA1-
mediated repair (10). For DNA lesions undergoing HR re-
pair, 53BP1 prevents excessive resection and favors gene
conversion over mutagenic single-strand annealing (11). In
the absence of functional BRCA1, the balance between HR
and NHEJ is tilted and DSB are improperly repaired by the
NHEJ pathway, leading to deleterious chromosomal aber-
rations. This effect is exploited in anticancer therapies with
PARP inhibitors (PARPi) (12). Acquired resistance limits
clinical efficacy of PARPi, and loss of 53BP1 function is
one of the mechanisms conferring PARPi tolerance in can-
cer cells (13–15). With the exception of BRCA-null tumors,
53BP1 functions as a tumor suppressor, the loss of which
radiosensitizes human (16) and mouse cells (17).
53BP1 is continuously expressed in the nucleus and
rapidly accumulates at ionizing radiation-induced foci
(IRIF) (18,19). The recruitment of 53BP1 to IRIF de-
pends on constitutive H4K20Me2 and damage-induced
H2AK15Ub marks recognized by the tudor and ubiquitin-
dependent recruitment (UDR) domains of the protein (20–
22). In the absence of DNA damage, the demethylase
JMJD2A and the Polycomb protein L3MBTL1 compete
with 53BP1 for H4K20Me2 binding sites; JMJD2A degra-
dation and L3MBTL1 eviction during the DDR facilitate
53BP1 binding to damaged chromatin (23,24). In addition,
the TIP60 acetyltransferase reduces 53BP1 binding to the
chromatin, tilting the repair balance towards HR: Acety-
lation of H4K16 decreases 53BP1’s affinity for H4K20Me2
(25), whereas H2AK15Ac prevents ubiquitination of the
same residue and 53BP1 UDR binding (26). Sustained
53BP1 function at IRIF also depends on 53BP1’s BRCTdo-
main binding to ATM-phosphorylated H2AX (27,28).
Less is known about the regulation of 53BP1 spatial dis-
tribution and function outside of repair foci. More gener-
ally, the mechanisms regulating the access of repair factors
to chromatin in the absence of DNA damage remain largely
unexplored.Yet suchmechanismsmay be key to prevent un-
due activation of the DDR. Here, we show that 53BP1 has
a slow nucleoplasmic diffusion behavior that accelerates in
response to DNA damage. We identify a novel interaction
between 53BP1 and the structural nuclear protein NuMA,
which regulates the mobility, IRIF formation, and function
of 53BP1.
MATERIALS AND METHODS
Cell culture, transfection and genotoxic treatments
Osteosarcoma U2OS cells were cultured in DMEM sup-
plemented with 10% fetal bovine serum (FBS, Sigma).
U2OS Lac-ISceI-Tet cells were obtained from T. Misteli
(NCI). Non-neoplastic breast epithelial cells (HMT-3522
S1) were cultured in H14 medium (29); HMT-3522 T4-
2 breast cancer cells were cultured in H14 without EGF.
SUM149PT breast cancer cells (obtained from E. Alli,
WFU) were cultured in DMEM supplemented with 10%
FBS and with 10 mM HEPES buffer, hydrocortisone (5
g/ml) and insulin (5 g/ml). CH12F3-2 cells were ob-
tained from T. Honjo (Kyoto University) and were cul-
tured in RPMI 1640 containing 2 mM L-glutamine, 10%
FBS and 50 M2-mercaptoethanol in vertically positioned
T25 flasks. Their density was kept below 105 cells/ml. My-
coplasma testing was performed yearly and results were sys-
tematically negative. Lipofectamine 3000 (ThermoFisher)
was used for siRNA (ON-TARGETplus, Dharmacon) and
for plasmid DNA transfection. The following expression
vectors were used for this study: GFP-53BP1 and GFP-
53BP1ct (encoding full length 53BP1 and residues 1200–
1711 of 53BP1 fused to GFP, respectively) (30); mCherry-
53BP1ct (Addgene plasmid # 19835) (31); GFP-Lac-NLS
(32); GFP-MeCP2 (33); GFP-PCNA (34); GFP-MDC1
(Addgene plasmid #26285); and mCherry-NuMA, cloned
by replacing GFP in GFP-NuMA (35) by mCherry us-
ing KpnI and BsrG1 restriction sites. GFP-NuMA(S395A)
was cloned by overlap PCR using the 5′ CAG CTG GAA
GAA CAC CTT gCg CAG CTG CAG GAT AAC CCA
C 3′ and 5′ GTG GGT TAT CCT GCA GCT GCG CAA
GGT GTT CTT CCA GCT G 3′ primer pair. The over-
lap PCR product was digested with EcoRV and AflII and
the fragment (1166 bp) was ligated into the correspond-
ing sites of pcDNA GFP-NuMA. Clones were verified us-
ing restriction for presence of the FspI site (introduced by
silent mutagenesis) and by DNA sequencing. The shRNA
vectors targeting human NuMA were purchased from Ori-
gene (TR311065). The shRNA vectors for murine proteins
were purchased from the Dharmacon RNAi Consortium
and included shNuMA-1 (TRCN0000072130), shNuMA-
2 (TRCN0000072132), and sh53BP1 (TRCN0000081778).
A shRNA scramble pLKO.1 plasmid (Addgene # 1864)
(36) was used as negative control. Lentiviral particles gener-
ated using HIV packaging were used for transduction. Sta-
bly silenced cell lines were generated after selection with
puromycin (0.6 g/ml). DNA damage was induced by
gamma irradiation (3 Gy and 10 Gy for S1 and U2OS
cells, respectively; Gammacell 220 irradiator from Nor-
dion), with the radiomimetic drug bleomycin (20 mU/ml
for 1 h), with mitomycin C (MMC; 2.6 M, 18 h), or with
hydrogen peroxide (1 mM, 10 min).
Modeling of protein diffusion
Simulations of protein diffusion in the nucleus were imple-
mented in MATLAB (MathWorks). All simulations were
performed at 37◦C. Macromolecules in solution undergo
random collisions from surrounding molecules, resulting in
a 3D translational or rotational random walk. 3D transla-













r ) is the displacement distribution of the
molecule, D is the diffusion coefficient, and  is the 3D
Laplace operator. Theoretically, the diffusion coefficient
has the following relationship with the size, d, of the macro-
molecules:
D = kBT
3 · π · η · d (2)
with kB, the Boltzmann constant, T the temperature, and η
the viscosity of the medium (1.5 × 10−3 Pa·s in the nucleus
(37). The diffusion coefficient can also be obtained from
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mean squared displacement (MSD) calculations, 〈(r )2〉. In
our model, we only considered the Brownian motion of the
protein in a 2D plane. Therefore,
(r )2 = 4 · D · t (3)
Witht, the lag time between each positionr.We simu-
lated the 2D Brownian motions of the proteins in time win-
dows of 1000 s and the trajectories (xi, yi) per second (t)
were registered for calculation. The displacementswere then
calculated as:
xi (t) = xi+1 − xi yi (t) = xi+1 − yi
xi (2t) = xi+2 − xi yi (2t) = xi+2 − yi
xi (N · t) = xi+N − xi yi (N · t) = yi+N − yi (4)
And the square displacement (r)2 was summarized as:
(ri (t))
2 = (xi (t))2 + (yi (t))2
(ri (2t))
2 = (xi (2t))2 + (yi (2t))2
(ri (N · t))2 = (xi (N · t))2 + (yi (N · t))2 (5)
The diffusion coefficientsD depend on the hydrodiameter
(hence the shape) of the molecules (equation 2). GFP has a
beta barrel structure of 4.2 nm in length (38), used for mod-
eling. To simulate GFP-53BP1 diffusion, we considered two
extreme possibilities, a single globular domain (sphere) and
a highly elongatedmolecule (rod). The corresponding phys-
ical sizes were predicted using a sedimentation model de-
scribed in (39). A sphere the size of GPF-53BP1 would have
a diameter of 8.22 nm, whereas the calculated length of the
rod would be 32.88 nm (using a sedimentation coefficient
Smax/S= 4). When predicting the sizes of 53BP1 dimers, we
considered combinations of spheres with minimum surface
(16.44 nm), as well as concatenated rods (65.56 nm). The
diffusion coefficients were obtained by fitting MSD curves
using equation (3).
Measurement of protein diffusion
Fluorescence correlation spectroscopy (FCS) measure-
ments were performed on a customized scanning confocal
microscope (Microtime 200, PicoQuant), as described pre-
viously (40). Cells were maintained at 37◦C and 5%CO2 us-
ing a stage-top incubator (Tokai Hit). GFP-53BP1 autocor-
relation curves were fitted using a two-components model,
which was validated by a maximum entropy method-based
fitting routine (MEM-FCS) (41). Optimal curve fitting was
achieved using a two-component Brownian model.
Continuous photobleaching (CP) measurements were
done using a Zeiss LSM880 scanning confocal microscope
equipped with a 63×water immersion objective (NA= 1.2)
and by point scanning of specific regions in the cell nu-
cleus. Points were continuously scanned at moderate laser
power (5%) over 7.8 s and fluorescence intensity was simul-
taneously recorded. Fluorescence intensity decay curves are
characterized by the dynamic equilibrium of photobleach-
ing and diffusion. CP curves for GFP-53BP1 and GFP-
MDC1 were fitted to a multi-exponential decay model (42–
44) as follows:
















The fast decay (first term in equation 6) represents the
fast initial photobleaching of the fluorescent molecules in
the focal volume, which was not considered for our analy-
ses. The second term represents the association/dissociation
behavior. We used  2 to derive the dissociation constant Kd
(42). Kd was normalized to the control condition since not
all CP constant parameters could be precisely estimated.
The third term characterizes the mobility of free-diffusing
molecules. Values of  3 were not affected by DNA damage.
For nontagged GFP, CP curves were best fitted using a two-
componentmodel ( 1, fast initial bleaching [not considered]
and  2, free diffusion).
Fluorescence loss in photobleaching (FLIP) assays were
performed using a Zeiss LSM710 confocalmicroscope, with
a 40× oil immersion lens (NA= 1.3). The 488 laser line was
used at 100% intensity to bleach regions of interests (ROIs)
corresponding to the upper half of the cell nuclei. This re-
gion was initially bleached using 2–3 scanning iterations.
Time-lapses were recorded (50 images over 1.5 min), alter-
nating bleaching of the upper-half of the nucleus and imag-
ing of the whole nucleus. GFP intensity was measured as a
function of time in elongated vertical rectangular ROIs be-
low the bleaching region. A single component decay curve
was used to fit the FLIP curves for the characteristic decay
time of the molecules (45).
Mass spectrometry
GFP-fused to 53BP1 containing amino acids 1–34 and
1220–1711 (30) was stably expressed in HEK293T cells
under the Tet-On promoter. Cells were exposed to doxy-
cycline (1 g/ml) for 72 h to induce expression of the
GFP-53BP1 construct. Cell lysates were immunoprecipi-
tated using GFP antibodies, resolved by SDS-PAGE, and
subjected to trypsin digestion. Peptides were separated by
HPLC and analyzed by LC-MS/MS using a LTQ Orbi-
trap XL (Thermo). Spectra were extracted by ProteoWiz-
ard andwere analyzed usingMascot (Matrix Science). Scaf-
fold (Proteome Software Inc.) was used to validate MS/MS
based peptide and protein identifications. Mass spectrom-
etry data are deposited in the MassIVE repository (https:
//massive.ucsd.edu; accession MSV000083293).
Immunoprecipitation and western blot analysis
For coimmunoprecipitation, nuclear extracts were pre-
pared using the Universal Magnetic Co-IP kit (Active
Motif) in the presence of protease inhibitors (aprotinin,
10 g/ml, Sigma; Pefabloc, 1 mM, Roche Applied Sci-
ence), phosphatase inhibitor (sodium fluoride, 250 M),
and PARG inhibitor (DEA, 10 M, Trevigen). Nuclear ex-
tracts (0.5 mg) were immunoprecipitated with NuMA an-
tibodies or nonspecific IgG (1.5 g) overnight at 4◦C, and
analyzed by immunoblotting. Similar results were obtained
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with two different NuMA antibodies (Calbiochem, ab-
2 and Bethyl Laboratories, A301-509A). Antibodies used
for immunoblot were 53BP1 (Abcam, Ab36823, 1 g/ml),
H2AX (Ser139; Millipore, clone JBW301, 1 g/ml), Hi-
stone H2B (Abcam, Ab1790, 0.1 g/ml), lamin B (Ab-
cam, Ab16048, 60 ng/ml), NuMA (B1C11, 1:2, a gift from
Dr Jeffrey Nickerson, UMass, Worcester, USA), P-NuMA
(S395; Cell Signaling, 3429, 1:1000), and PAR (Trevigen,
4336-APC-050, 1:1000).
Immunostaining
Immunostaining was performed as described (40). Anti-
bodies used for immunofluorescence were 53BP1 (Abcam,
5 g/ml), H2AX (Millipore, 2 g/ml), NuMA (B1C11,
1:2 or Abcam, clone EP3976, 1:250), P-NuMA (Cell Signal-
ing, 1:200), and SNF2h (Abcam Ab3749, 20 g/ml). Flu-
orescent signals were imaged with a Zeiss LSM710 confo-
cal microscope using a 63× oil (NA = 1.4) objective. Imag-
ing fields were randomly selected based on DAPI signals.
Repair foci were quantified using a custom macro in Im-
ageJ (http://rsbweb.nih.gov/ij/). For experiments compar-
ing HMT-3522 S1 cells transfected with nontargeting and
NuMA-targeting siRNA, the macro included a step to sub-
tract NuMA-derived masks from DAPI-derived masks of
the nuclei, in order to exclude cells retaining NuMA expres-
sion in the siNuMA conditions.
FRET and laser microirradiation
Acceptor photobleaching FRET experiments were per-
formed using a Zeiss LSM710 confocal microscope using
a 63x water objective (NA = 1.3). mCherry (FRET accep-
tor) was bleached in spot areas of the cell nucleus using
three pulse iterations (561 diode laser at 100% power and
177 s/pixel dwell time). FRET efficiency was calculated as
E = ((I[post-bleach] – I[pre-bleach])/I[post-bleach]) x 100. To induce
DNA damage by laser microirradiation, the 405 nm laser
line of the LSM710 was used at maximum power to draw
lines across nuclei (100 s dwelling time; ∼1 s scan/line).
Cells were sensitized with BrdU (10 M) 48 h prior to mi-
croirradiation and were irradiated and imaged with the 63x
water immersion lens. In all assays involving live cell imag-
ing, cells in glass-bottom dishes (MatTek) were maintained
at 37◦C and 5% CO2 with a stage-top incubator (Pecon).
GFP-based repair assays and cell cycle analysis
NHEJ was assessed in U2OS cells with a stable integra-
tion of the NHEJ-I reporter cassette, as described (46). The
NHEJ reporter is composed of the GFP coding sequence
interrupted by an exogenous exon flanked by ISceI recog-
nition sites. NHEJ reconstitutes the GFP coding sequence
after ISceI cleavage. GFP-positive cells were quantified by
flow cytometry 24 h after ISceI transfection. 10 000–100
000 cells were analyzed in each sample. Cells were costained
with DRAQ5 (Biostatus) to collect DNA content values for
cell cycle determination.
Class switch recombination (CSR)
CH12F3-2 cells were nucleofected with shRNA vectors and
overexpression plasmids (LonzaNucleofector™ I device; so-
lution L; program T20; 106 cells and 2 g DNA per reac-
tion). CSR to IgA was induced by stimulating the cells for
72 h with 5 g/ml agonist anti-CD40 (clone HM40-3; BD),
5 ng/ml IL-4 (R&DSystems) and 2.5 ng/mlTGF-1 (R&D
Systems). Surface expression of IgA was analyzed by flow
cytometry using PE-conjugated goat antimouse IgA anti-
bodies (1:400; SouthernBiotech).
Quantification of chromosomal aberrations
SUM149PT cells were seeded in 6-well plates (one plate
per condition) and cultured until they reached 60% conflu-
ency for transfection. GFP and GFP-NuMA overexpress-
ing cells were selected with geneticin (200 g/ml). To quan-
tify chromosomal aberrations, the cells were transferred
onto 22× 22mmcoverslips in 35mmdishes 48 h after trans-
fection. Cells were then treated with PARP inhibitor (ola-
parib; 0.5 M) or vehicle. After 24h incubation, colcemid
(10g/ml) was added to the cells for 1h.Metaphase spreads
were prepared by hypotonic bursting in (2:1) (75 mM KCl:
0.8% sodium citrate) and fixation in (3:1) (methanol: acetic
acid). Subsequently, coverslips were air dried, mounted on
microscope slides, stained with 2% Giemsa for 3 min and
washed in Gurr buffer. Slides were allowed to dry and were
analyzed with an Olympus IX83 microscope using a 60×
oil objective and CMOS camera (ORCA-Flash4.0; Hama-
matsu).
Human breast tissues
Breast invasive ductal carcinoma tissueswere obtained from
mastectomies and normal breast tissue was obtained from
reduction mammoplasties, after obtaining patient consent
(Purdue Institutional Review Board approval 1206012467).
The excision specimen were resected, minced to approx.
4 mm fragments, and placed in RPMI within 30 min of
surgery. Tissue explants were rinsed with, and transported
in RPMI. After irradiation (3 Gy; Gammacell 220 irra-
diator) and recovery in a tissue culture incubator (37◦C;
5% CO2), tissue explants were incubated in PBS contain-
ing 18% sucrose on ice for 15 min, then with PBS with
30% sucrose on ice for 15 min, and frozen in optimal cut-
ting temperature (OCT) compound on dry ice mixed with
70% ethanol. Controls were mock-irradiated. Tissues were
stored at −80◦C until sectioning of 12 m thick sections
with a cryostat set at −20◦C. Tissue slices were collected on
Superfrost plus slides and used for immunostaining.
Analysis of tumor expression profiles
Breast tumor expression profiles generated by The Can-
cer Genome Atlas (TCGA) Research Network (http://
cancergenome.nih.gov/) and the microarray dataset of Na-
galla et al. (47) were utilized in this study. The TCGA
clinical data and RNA-seq data (level 3-processed) were
downloaded from the Broad’s FireBrowse website (http:
//firebrowse.org/; TCGA data version 2016 01 28). The
RNA-seq breast tumor data comprising 1100 tumor expres-
sion profiles was filtered to exclude male and gender ‘un-
known’ samples (n = 13), metastatic tissue samples (n = 7)
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and one errant skin cancer sample yielding 1079 female pri-
mary breast tumor samples. OncoLnc (http://www.oncolnc.
org) was used to visualize overall survival (48).
Statistical analysis
Statistical analyses were done using GraphPad Prism 6.0.
Data are presented as mean ± SEM or mean± SD, as indi-
cated in the figure legends. The D’Agostino & Pearson om-
nibus normality test was used to test for normality before
computing either t-test or one-way ANOVA and post-hoc
tests. Nonparametric tests were used if the data did not pass
the normality test (at alpha= 0.05). Statistical tests are indi-
cated in the figure legends, whereas exact p-values are shown
in the figures. All statistical tests were two-sided.
RESULTS AND DISCUSSION
53BP1 movements are restrained in the nucleoplasm
The mechanisms that govern the spatial kinetics of 53BP1
in the absence ofDNAdamage are largely unknown. There-
fore, we measured diffusion of GFP-tagged 53BP1 in re-
gions of the nucleoplasm devoid of DNA breaks using flu-
orescence correlation spectroscopy, and compared the val-
ues with predictions generated with a diffusion model (Fig-
ure 1A). Theoretical diffusion values for GFP alone and
for a fluorescent protein tandem concurred with FCS mea-
surements, which validated our model. For GFP-53BP1, we
used hydrodiameters corresponding to sphere or rod struc-
tures to predict diffusion because the full structure of 53BP1
is unknown. The FCS curves for GFP-53BP1 were best fit-
ted with a two-component model interpreted as slow move-
ments (0.5 m2/s) coexisting with rapid Brownian motions
(23.2 m2/s), although we cannot exclude some contribu-
tion of directed motions. The ‘Brownian’ diffusion values
matched well with the predicted diffusion value assuming
a spherical structure of 53BP1, indicating that 53BP1 is
likely to adopt a compact native conformation. In contrast,
the second component of GFP-53BP1 diffusion was signif-
icantly slower than the predictions, even when considering
53BP1 dimers in the model (Supplementary Table S1). We
conclude that 53BP1 diffusion is constrained in the cell nu-
cleus.
A previous study determined the steady state kinetics of
two other NHEJ factors, KU80 (14 m2/s) and DNA-PKc
(6m2/s) (49). These measurements are similar to the theo-
retical values for KU80 and DNA-PKc computed with our
diffusion model (Supplementary Table S1). Hence, the con-
cept of restricted diffusion that we put forward for 53BP1
might apply to some but not all DDR proteins.
DNA damage increases 53BP1 mobility
To test whether the constraints on 53BP1 are modulated
during theDDR, diffusion ofGFP-53BP1wasmeasured by
FCS in the absence and presence of DNA damage induced
with ionizing radiations (IR) or with the radiomimetic drug
bleomycin. Association of 53BP1 with the chromatin flank-
ing DNA breaks strongly reduces 53BP1 mobility (50).
To avoid this effect, we selected regions in-between re-
pair foci for FCS point measurements. Exposures to IR
and bleomycin both lead to a significant increase in GFP-
53BP1 mobility outside repair foci (Figure 1B). This in-
crease could not be explained by altered nucleoplasm vis-
cosity since the kinetics of GFP alone remained unchanged
after DNA damage. We used two independent approaches
to further assess 53BP1 motions in response to DNA dam-
age, continuous photobleaching (CP) and fluorescence loss
in photobleaching (FLIP). The dissociation constant Kd
was extracted from CP measurements. In cells treated with
bleomycin, Kd for GFP-53BP1 was significantly increased
compared to control (Supplementary Figure S1A). We in-
terpret this increased dissociation rate as the release of
53BP1 from an immobile binding site. No differences in CP
measurements were measured for GFP alone. We also per-
formed CP measurements for MDC1, a DDR factor with
a molecular size similar to that of 53BP1. Unlike GFP-
53BP1, Kd for GFP-MDC1 was decreased in cells with
DNA damage (albeit not significantly), possibly reflect-
ing an overall increased association with chromatin (Sup-
plementary Figure S1A). In FLIP experiments, diffusion
times for GFP-53BP1 significantly decreased in cells treated
with bleomycin (Supplementary Figure S1B), meaning that
53BP1 became more mobile in cells with DNA damage, as
measured with FCS. Our biophysical results are consistent
with biochemical fractionation experiments that detected
53BP1 in the insoluble nuclear fraction in the absence of
DNA damage and in the chromatin fraction after IR (51).
These findings suggest a mechanism increasing 53BP1 nu-
cleoplasmic mobility in response to DNA damage.
53BP1 interacts with the nucleoskeletal protein NuMA
We used a proteomics approach to identify factors inter-
acting with 53BP1 and regulating its dynamics in the nu-
cleus. We short-listed 53BP1 binding candidates identified
in this study and in previous analyses of the 53BP1 inter-
actome deposited in PubMed or in the BioGrid database
(http://thebiogrid.org/) (Supplementary Tables S2 and S3).
Among these proteins, the nuclear mitotic apparatus pro-
tein (NuMA) was identified with the highest confidence in
our analysis.
NuMA is a structural nuclear protein with a well-
established function in spindle pole assembly and mainte-
nance (52,53). In addition tomitotic functions,NuMA is es-
sential for the establishment of higher-order chromatin or-
ganization during epithelial cell differentiation (54,55) and
for DNA repair by HR (40). Co-immunoprecipitation (IP)
experiments using NuMA antibodies confirmed the inter-
action between endogenous 53BP1 and NuMA in U2OS
osteosarcoma cells, in HMT-3522 T4-2 breast cancer cells,
and in non-neoplastic HMT-3522 S1 mammary epithelial
cells (Figure 1C and Supplementary Figure S2A). Inter-
action between the two proteins decreased after DSB in-
duction with ionizing radiations, but not after a short ex-
posure to hydrogen peroxide used as a source of oxida-
tive DNA damage (Figure 1C and Supplementary Figure
S2B). Fluorescence resonance energy transfer (FRET) ex-
periments showed that mCherry-tagged NuMA interacts
with GFP-53BP1 and that NuMA-53BP1 interaction de-
creases in cells with DNA damage (Figure 1D). FRET ex-
periments also indicated interaction between NuMA and
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Figure 1. NuMA interacts with 53BP1 and regulates 53BP1 kinetics. (A) Modeling of GFP-53BP1 diffusion, assuming either a spherical or a rod-shaped
structure of the protein. GFP and a fluorescent protein tandem (GFP-mCherry) were used as controls. Time trace simulations are shown with the predicted
diffusion times and experimental FCS values (mean± SEM; n≥ 15). (B) Diffusion of GFP-53BP1 and GFPmeasured by FCS. U2OS cells were untreated
(control), treated with bleomycin (20 mU/ml, 1 h), or exposed to ionizing radiations (IR, 10 Gy and 30 min recovery). n = 50–60 cells from 2 biological
replicates; Mann–Whitney test. (C) Immunoprecipitation of NuMA from U2OS nuclear extracts (N.E.). Nonspecific immunoglobulins (IgGs) were used
as controls. Blots were probed for NuMA and 53BP1. Cells were exposed to IR (10 Gy, and 30 min recovery) or treated with H2O2 (1 mM, 10 min) prior
IP. Densitometric quantification of 53BP1 pull down is shown on the graph (mean ± SEM; one sample t-test; n = 4 (IR) or 3 (H2O2)). In the right panel
(H2O2 treatment), all lanes are from the same immunoblot membrane and were taken with the same exposure. Lanes were reassembled for clarity. (D)
FRET efficacy in U2OS cells expressing NuMA fused to mCherry and either GFP (used as control), GFP-53BP1, or GFP-53BP1ct (mean± SD; n= 20–25
cells from at least two experiments; Kruskal–Wallis and Dunn’s multiple comparison test). (E) Colocalization (arrowheads) between 53BP1 foci and bright
NuMA features in immunostaining images of S1 cells treated with bleomycin or untreated (control). Scale bar, 5 m. Overlap is quantified on the graph
(mean ± SEM; n = 10 images from two experiments, corresponding to 300 nuclei per condition; Student’s t-test). (F) FCS analysis of GFP-53BP1, GFP,
and GFP-MeCP2 diffusion. Cells were transfected with nontargeting (NT) or with NuMA-targeting siRNA and were treated with bleomycin as indicated.
Statistical analysis with one-way ANOVA and Tukey (GFP-53BP1) or Mann–Whitney tests (GFP and GFP-MeCP2). NuMA silencing was verified by
western blot, with lamin B as loading control.
the minimal focus-forming region of 53BP1 (residues 1200–
1711; GFP-53BP1ct) that contains 53BP1’s oligomeriza-
tion, tudor, and UDR domains. These results suggest that
NuMA interacts with a region of 53BP1 that is critical for
chromatin binding. We can however not exclude the possi-
bility that NuMA interacts with another portion of 53BP1
(or that the interaction is indirect). Indeed, the oligomariza-
tion domain in GFP-53BP1ct may allow the formation of
heterodimers with full-length endogenous 53BP1 in these
experiments.
To further address the link between NuMA and 53BP1,
the relative distribution of the two proteins was quanti-
fied by immunostaining. A subset of 53BP1 nuclear bod-
ies overlapped with bright NuMA signals in untreated cells.
In bleomycin-treated cells, this colocalization decreased sig-
nificantly, as revealed by visual scoring (Figure 1E) and
by computingMander’s colocalization coefficients (Supple-
mentary Figure S2C). 53BP1 nuclear bodies in nondam-
aged cells correspond to dysfunctional telomeres (56) as
well as ‘shielded’ mitotic lesions (57). The latter are gener-
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ally found in G1 cells and may contain complex DNA le-
sions that require the HR pathway for repair. 53BP1 bod-
ies have been proposed to provide a protective environment
inhibiting transcription and delaying repair until the appro-
priate cellular context arises, such sister chromatid synthesis
during S-phase (58). Hence, 53BP1 bodies are distinct from
53BP1 IRIF induced by drugs and radiations. The loss of
colocalization between NuMA and 53BP1 nuclear bodies
and the loss of interaction between NuMA and 53BP1 af-
ter DNA damage induction suggest that NuMA regulates
53BP1 function during the initial response to DNA dam-
age.
NuMA reduces 53BP1 mobility outside repair foci
The DNA damage-dependent interaction and colocaliza-
tion between 53BP1 and the structural protein NuMA
prompted us to test if NuMA regulates the dynamics of
53BP1 in the cell nucleus. Mobility of GFP-53BP1 at nu-
clear regions lacking damage foci was significantly higher
in cells silencing NuMA compared to controls (Figure 1F).
This increase was similar to the increased diffusion result-
ing fromDNAdamage induction with bleomycin, and both
treatments had no additive effect. Silencing NuMA did not
alter the dynamics of GFP orGFP fused to the methyl CpG
binding protein 2 (GFP-MeCP2), nor cause DNA dam-
age (see next section). FLIP experiments confirmed the in-
creased 53BP1 diffusion in cells silencing NuMA compared
to controls (Supplementary Figure S1B). Hence, NuMA
may reduce 53BP1 diffusion in the absence of DNA dam-
age.
NuMA depletion does not alter 53BP1 expression
NuMA is structurally related to nuclear lamins, which
have been shown to stabilize 53BP1 (59). In contrast to
laminA/C depletion, NuMA silencing did not alter 53BP1
levels (Figure 2A). Silencing NuMA had also no effect on
53BP1 levels in cells with DNA damage (Supplementary
Figure S2D). Hence, NuMA does not regulate 53BP1 ex-
pression but may rather sequestrate 53BP1 in the absence of
damage to keep this master DDR effector in check.We note
that other studies have shown degradation of 53BP1 by the
proteasome after DNA damage (60,61). This effect was not
observed in U2OS or HMT-3522 S1 cells in our experimen-
tal conditions, possibly due to cell line-specific expression
and compartmentalization of the protein.
NuMA antagonizes 53BP1 recruitment at DNA breaks
To test if NuMA influences 53BP1 accumulation at DNA
repair foci, HMT-3522 S1 mammary epithelial cells were
transfected with NuMA-targeting or with nontargeting
siRNA and exposed to IR. Increased 53BP1 foci density
was measured in cells silencing NuMA compared to the
nontargeting siRNA controls (Figure 2A). We also com-
pared NuMA-positive and NuMA-negative cells within the
NuMA siRNA transfections and found that irradiated cells
with NuMA expression had significantly less 53BP1 foci
compared to cells with no detectable NuMA expression
(Figure 2A). We excluded that NuMA silencing sensitized
the cells to IR because similar amounts of DSB were de-
tected using the comet assay in siNuMA transfectants and
controls (Supplementary Figure S3A). Moreover, cell cycle
distribution - an important factor in repair pathway choices
- was not affected by NuMA depletion in S1 cells (Fig-
ure 2B). Increased 53BP1 foci numbers were also measured
in bleomycin-treated S1 cells expressing NuMA-targeting
shRNA (Supplementary Figure S3B) and a similar effect
wasmeasured forGFP-53BP1 inU2OS cells, where siRNA-
mediated NuMA depletion lead to increased GFP-53BP1
foci formation in response to bleomycin or mitomycin C
(Supplementary Figure S3C).
Next, we asked if NuMA affects 53BP1 accumulation
at single DSB using a cell system with a stable integra-
tion of the ISceI cleavage site flanking lac arrays. 53BP1
foci at cleaved arrays were brighter in cells with NuMA
silenced compared to controls (Figure 2C). In addition,
NuMA overexpression decreased GFP-53BP1 and GFP-
53BP1ct accumulation at laser-microirradiated tracks and
silencing NuMA lead to increased GFP-53BP1ct line ac-
cumulation in microirradiated cells (Figure 2D and Sup-
plementary Figure S3D). Altering NuMA expression did
not perturb recruitment of GFP-PCNA and GFP-MDC1
to the laser tracks (Supplementary Figure S3D–E), ruling
out nonspecific effects and indicating that NuMA’s effect
on 53BP1 is likely independent from the MDC1-RNF8-
RNF168 cascade that mediates chromatin recognition by
53BP1 (5).
Pan-nuclear NuMA phosphorylation regulates 53BP1 accu-
mulation at sites of DNA damage
We showed previously that NuMA regulates SNF2h accu-
mulation at DNA breaks (40). Yet silencing SNF2h did not
alter 53BP1 line formation in microirradiation assays (Sup-
plementary Figure S3F), suggesting that SNF2h does not
mediate the spatial regulation of 53BP1 by NuMA. These
results are in agreement with a previous report showing no
defect in 53BP1 IRIF formation in SNF2h-depleted cells
(62).
NuMA is an ATM substrate that is rapidly phosphory-
lated at serine 395 in response to IR (40,63) (Figure 2E).
Immunostaining with P-NuMA antibodies after bleomycin
treatment or laser microirradiation revealed pan-nuclear
NuMA phosphorylation in response to DNA damage (Fig-
ure 2E and Supplementary Figure S3G). To determine
if NuMA phosphorylation may regulate 53BP1 accumu-
lation at damaged chromatin, we first compared GFP-
53BP1ct accumulation at laser microirradiated sites in cells
treated with an ATM inhibitor (ATMi) versus vehicle. The
ATMi treatment significantly reduced GFP-53BP1ct line
formation (Supplementary Figure S3H). We could how-
ever not exclude pleiotropic effects of ATMi on 53BP1ct
accumulation to DNA damage sites and therefore com-
pared 53BP1 line formation in cells expressing GFP, GFP-
NuMA, or GFP fused to a nonphosphorylatable NuMA
mutant [GFP-NuMA(S395A)]. Whereas GFP-NuMA ex-
pression reduced 53BP1 line accumulation by approxi-
mately 50%, expression of the nonphosphorylatable mutant
almost completely abrogated 53BP1 recruitment to DNA
damage sites (Figure 2F). Together, the data suggest that
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Figure 2. NuMA antagonizes 53BP1 accumulation at DNA damage sites. (A) Left: NuMA silencing and 53BP1 expression analyzed by western blot in
HMT-3522 S1 cells transfected with nontargeting (NT) or NuMA-targeting siRNA. Right: IR-induced focal accumulation of 53BP1 in S1 cells transfected
with siNT and siNuMA. Confocal images show NuMA and 53BP1 immunostaining in irradiated cells (3 Gy, 2h recovery). The arrowhead points to a cell
retainingNuMAexpression in contrast to its neighbors. Quantification of 53BP1 foci is presented in the box-and-whisker plot. *P< 0.05 and ***P< 0.0001
(one-way ANOVA and Bonferroni’s test; n= 4; 100–300 cells analyzed per condition for each replicate). The inset shows the average number of 53BP1 foci
per nucleus in cells that lost (–) or retained (+) NuMA expression within the siNuMA transfection condition. #P < 0.05 (Student’s t-test). (B) Cell cycle
distribution in S1 cells transfected with NT and NuMA siRNA determined by flow cytometry (mean ± SEM; n= 4; Student’s t-test). (C) Accumulation of
53BP1 at ISceI sites in U2OS cells transfected with NT and NuMA siRNA. Cleavage sites were identified using the Lac arrays flanking the ISceI site and
53BP1 was detected by immunostaining. n > 40 cells from three replicates; Student’s t-test. (D) Accumulation of GFP-53BP1ct at laser-microirradiated
tracks (arrowheads) in U2OS cells expressing mCherry or mCherry-NuMA (insets) or transfected with NT and NuMA-targeting siRNA. The fraction
of GFP signal at the tracks is shown on the bar graphs (mean ± SEM, Mann-Whitney test). (E) NuMA phosphorylation at Ser395 (P-NuMA) after
DNA damage. Left: western blot analysis. Total NuMA and lamin B were used as loading controls. Right: immunostaining of cells transfected with NT
or NuMA siRNA. The arrow points to P-NuMA signals in a cells expressing NuMA. (F) Accumulation of mCherry-53BP1ct after laser-microirradiation
in cells expressing GFP, GFP-NuMA, or a nonphosphorytable NuMA mutant [GFP-NuMA(S395A)] (mean ± SEM, Mann-Whitney test). Arrowheads
indicate the position of the laser microirradiation tracks. Scale bars, 10 m.
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NuMA acts as a barrier preventing 53BP1 accumulation
at damaged chromatin. NuMA phosphorylation by ATM
may serve as a release mechanism.
NuMA negatively regulates 53BP1 function
53BP1 is essential for immunoglobulin class switch recom-
bination (CSR) during B cell maturation (64,65), a process
where DSB induced in the immunoblobulin heavy chain
gene are re-ligated by long-range NHEJ. We confirmed that
silencing 53BP1 in CH12F3-2 murine B cells reduces im-
munoglobulin switching to the IgA class (Figure 3A). Next,
we found that GFP-NuMA overexpression markedly re-
duced CSR and expression of the phospho-null NuMAmu-
tant further exacerbated the CSR defect (Figure 3A).
In breast and ovarian tumors with BRCA1 muta-
tions, loss of 53BP1 was shown to partially restore HR,
thereby reducing PARP inhibitor toxicity (13,14). As ex-
pected, siRNA-mediated depletion of 53BP1 in BRCA1-
null SUM149PT breast cancer cells decreased the fre-
quency of chromosomal aberrations in response to the
PARP inhibitor olaparib (Figure 3B). GFP-NuMA over-
expression significantly reduced olaparib efficacy, similarly
to 53BP1 loss.Moreover, combiningNuMAoverexpression
and 53BP1 silencing did not have an additive effect, suggest-
ing epistasis of the two proteins (Figure 3B).
An important function of the 53BP1-RIF1 complex is
to promote NHEJ by preventing DSB end-resection, the
committing step for HR. In cells overexpressing mCherry-
NuMA, NHEJ activity was decreased by 50% relative to
controls expressing mCherry only (Figure 3C). In addi-
tion, the proportion of NHEJ-competent (GFP-positive)
cells with mCherry signals was significantly reduced in the
mCherry-NuMA transfections compared to the mCherry
transfection, although the transfection efficiencies for
mCherry and for mCherry-NuMA were not different (32
± 4% versus 34 ± 4%, respectively).
From three independent assays (CSR, PARPi sensitiv-
ity of BRCA1-deficient cells, and NHEJ efficacy), we con-
clude that NuMA negatively regulates 53BP1 function. As
such, NuMA may phenocopy the tudor interacting re-
pair regulator (TIRR), a soluble factor binding to 53BP1
and preventing 53BP1 interaction with H4K20Me2 (60,66–
69). Similar to 53BP1-NuMA, the interaction between
53BP1 and TIRR was shown to decrease in response to
DNA damage, enabling 53BP1 chromatin binding and
DDR functions (60). Interestingly, the association between
53BP1 and its previously characterized partners––as well
as NuMA––increased in cells depleted from TIRR (60).
Whereas TIRR stabilizes 53BP1 in the nuclear-soluble frac-
tion (60), 53BP1 also resides in the insoluble fraction of
the cell nucleus (51), where NuMA is found as well (54,70).
Hence, distinct negative regulators may control (and pos-
sibly compete for) 53BP1 in the different compartments of
the nucleus.
NuMA expression predicts survival in breast cancer patients
To address the in vivo relevance of 53BP1 regulation by
NuMA, invasive ductal carcinoma (IDC) tissue samples
were collected after surgery, irradiated, and left to recover
in medium for one or six hours. As expected, the number
of 53BP1 IRIF increased in irradiated tissues compared to
nonirradiated controls and subsequently decreased after the
recovery period (Figure 4A). NuMA was detected in dis-
crete nuclear spots, as shown previously (54). Strikingly, the
majority of the large 53BP1 nuclear bodies in nonirradi-
ated cells overlapped with the NuMA spots. As measured in
cell culture, colocalization between NuMA and 53BP1 de-
creased after IR in the tissue samples (Figure 4A and Sup-
plementary Figure S4A). After six hours recovery, the over-
lap between the two proteins went back to the levels found
in the nonirradiated controls, consistent with an initial ob-
servation that interaction between 53BP1 and NuMAmea-
sured by mass spectrometry was not different at a late time
point after IR (24h). We noticed and quantified large vari-
ations in NuMA expression within IDC samples (but not
in normal breast tissues derived from reduction mammo-
plasties; Supplementary Figure S4B). This heterogeneity in
NuMA levels enabled us to ask if NuMA expression affects
53BP1 foci formation. As observed in vitro, NuMA levels
negatively correlated with 53BP1 foci densities in irradiated
IDC cells (Figure 4B).
53BP1 repair function in cancer cells may promote can-
cer cell resistance to IR and chemotherapy (with the no-
table exception of BRCA1−/− tumors) by enabling repair
as well as by fueling genomic instability that results from
nonhomologous end-joining. Indeed, increased radiosensi-
tivity has beenmeasured in 53BP1-deficientmice (17) and in
glioblastoma tumors with very low levels of 53BP1 (16). A
negative regulator of 53BP1 may affect cancer cell survival
in the presence of DNA damage and hence, cancer treat-
ment responses. We therefore examined NuMA gene ex-
pression levels in the Cancer GenomeAtlas (TCGA) cohort
and in an independent microarray analysis of breast tumors
(47). In both cohorts, we observed a significant but moder-
ate positive correlation between NUMA1 and 53BP1 tran-
script levels (Figure 4C and Supplementary Figure S4B). It
remains to be seen if NuMA and 53BP1 protein levels are
correlated as well in patient cohorts.
More importantly, NUMA1 expression was significantly
associated with patient distant metastasis-free survival by
Kaplan-Meier analysis in the microarray dataset, and strat-
ification of tumors based on NUMA1 messenger levels re-
vealed a significant increase in survival for patients with tu-
mors with high NUMA1 expression (Figure 4D). This ef-
fect persisted when only basal-like tumors were analyzed,
indicating that the good prognosis associated with high
NUMA1 expressionwas not due to the enrichment of breast
cancer subtypes with better outcomes among NUMA1-
high cases (Supplementary Figure S4C). Accordingly, high
NUMA1 predicted longer overall survival in patients from
the TCGA cohort (Supplementary Figure S4E).
CONCLUSION
Little is known about regulation ofDNA repair factors out-
side of the context of DNA repair foci. Here, we present
data supporting a sequestration mechanism for 53BP1,
which may prevent activation of the DNA damage response
in the absence of DNA damage. Using multiple biophysi-
cal approaches (FCS, CP, and FLIP), we show that 53BP1
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Figure 3. NuMA negatively regulates 53BP1 function. (A) CSR in CH12F3-2 B cells stably expressing scrambled and 53BP1 shRNA, or nucleofected to
express GFP, GFP-NuMA, and GFP-NuMA(S395A) (mean ± SEM; n≥ 3, ANOVA and Tukey). Representative flow cytometry contour plots are shown
for cell nucleofected with GFP and GFP-NuMA constructs. 53BP1 silencing was verified by western blot (right). (B) Chromosomal aberrations (radials +
fusions) in BRCA1-null SUM149 cells transfected with nontargeting or 53BP1-targeting siRNA, GFP, or GFP-NuMA. Cells were treated with olaparib
(0.5 M; 24 h). n = 40–120 cells from ≥3 replicates; statistical analysis with ANOVA and Tukey. Representative images of metaphases are displayed, with
arrowheads indicating aberrations. Western blot (right) verified 53BP1 silencing and GFP-NuMA expression (upper band). (C) Quantification of NHEJ in
U2OS cells with a stably integratedNHEJ-GFP reporter (left; mean± SEM; Student’s t-test). The fraction of cells expressingmCherry or mCherry-NuMA
among GFP-positive cells is shown in the cross-ruled graph, whereas cell cycle distribution is shown on the right.
movements are restrained in regions of the nucleus devoid
of repair foci, and that 53BP1 mobility increases in these re-
gions after DNAdamage induction.We identify interaction
between 53BP1 and the structural nuclear protein NuMA
that may be key to the proposed sequestration mechanism
based on our observations that (i) NuMA depletion in-
creases 53BP1 mobility, (ii) 53BP1 interaction and colo-
calization with NuMA decrease in response to DSB, (iii)
NuMA antagonizes 53BP1 repair foci formation, and (iv)
53BP1 DSB repair functions are negatively regulated by
NuMA, which is worthwhile considering in light of the pre-
viously established pro-HR function of NuMA (40). It will
be interesting to assess if and how NuMA influences ad-
ditional 53BP1-dependent cellular outcomes; in particular
the fusion of dysfunctional telomeres (31). Also, the 53BP1-
NuMA release mechanism and the structural basis for the
interaction deserve further investigation. Both aspects are
likely to involve NuMA phosphorylation by ATM, which
we find occurs rapidly throughout the nucleus in response
to DSB. NuMA expression and localization is frequently
altered in cancer cells (71,72) and our analyses show high
intra- and intertumor heterogeneity inNuMA levels, as well
as a significant survival gain associated with high NUMA1
gene expression in breast cancer patients. NuMA’s mitotic
function may influence therapeutic responses. In addition,
the new results presented here suggest that NuMAmay sup-
press the DSB repair function of 53BP1, in particular mu-
tagenic NHEJ linked to 53BP1 overexpression (73), thereby
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Figure 4. NuMA expression predicts survival in breast cancer patients. (A) Confocal images of 53BP1 and NuMA immunostaining in invasive ductal
carcinoma (IDC). Tissue explants were mock-irradiated (control) or exposed to IR (3 Gy) and left to recover for 1 or 6 h. Arrowheads point to colocalized
foci. Scale bar, 10 m. 53BP1 foci numbers and the overlap between 53BP1 foci and bright NuMA features are quantified in the graphs (mean ± SEM; n
= 3 [50–300 foci counted per condition in each sample]; Student’s t-test). (B) Correlation between NuMA expression and 53BP1 foci density in irradiated
tissues (IDC patients #005–7). Left: representative confocal images. NuMA staining intensity is visualized with a heat map. Center: normalized NuMA
intensities are plotted against the densities of 53BP1 foci for each cell nucleus. n= 281; Spearman’s p-value is indicated. Right: average foci densities in cells
with low NuMA (first quintile) and high NuMA (last quintile) (mean ± SEM; n = 56; Mann–Whitney test). Scale bar, 10 m. (C) Correlation analysis of
NUMA1 and TP53BP1 mRNA expression levels in 1954 breast tumors analyzed by microarray. Data are expressed as log2 normalized signal intensities.
Spearman correlation (rs) and the corresponding P-value are shown. (D) Kaplan–Meier plot of distant metastasis-free survival (DMFS) with patients
stratified by NUMA1 expression quartiles. The log-rank P-value is shown.
increasing tumor sensitivity to genotoxic anticancer treat-
ments and loweringmutagenic rates that contribute to treat-
ment resistances. These effects may be exploited for thera-
peutic purposes.
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